190 related articles for article (PubMed ID: 26219569)
1. P-glycoprotein confers acquired resistance to 17-DMAG in lung cancers with an ALK rearrangement.
Kim HJ; Lee KY; Kim YW; Choi YJ; Lee JE; Choi CM; Baek IJ; Rho JK; Lee JC
BMC Cancer; 2015 Jul; 15():553. PubMed ID: 26219569
[TBL] [Abstract][Full Text] [Related]
2. [Effects of 17-DMAG on non-small cell lung cancer cell lines A549 and H1975
being resistant to EGFR-TKI].
Zhao L; Cao F
Zhongguo Fei Ai Za Zhi; 2014 Nov; 17(11):778-82. PubMed ID: 25404267
[TBL] [Abstract][Full Text] [Related]
3. Afatinib Overcomes Pemetrexed-Acquired Resistance in Non-Small Cell Lung Cancer Cells Harboring an EML4-ALK Rearrangement.
Kwon JH; Kim KJ; Sung JH; Suh KJ; Lee JY; Kim JW; Kim SH; Lee JO; Kim JW; Kim YJ; Lee KW; Kim JH; Bang SM; Kim S; Yoon SS; Lee JS
Cells; 2019 Nov; 8(12):. PubMed ID: 31795298
[TBL] [Abstract][Full Text] [Related]
4. The anti-proliferative effect of heat shock protein 90 inhibitor, 17-DMAG, on non-small-cell lung cancers being resistant to EGFR tyrosine kinase inhibitor.
Kobayashi N; Toyooka S; Soh J; Yamamoto H; Dote H; Kawasaki K; Otani H; Kubo T; Jida M; Ueno T; Ando M; Ogino A; Kiura K; Miyoshi S
Lung Cancer; 2012 Feb; 75(2):161-6. PubMed ID: 21767894
[TBL] [Abstract][Full Text] [Related]
5. Hsp90 inhibition overcomes HGF-triggering resistance to EGFR-TKIs in EGFR-mutant lung cancer by decreasing client protein expression and angiogenesis.
Koizumi H; Yamada T; Takeuchi S; Nakagawa T; Kita K; Nakamura T; Matsumoto K; Suda K; Mitsudomi T; Yano S
J Thorac Oncol; 2012 Jul; 7(7):1078-85. PubMed ID: 22592212
[TBL] [Abstract][Full Text] [Related]
6. Activation of HER family signaling as a mechanism of acquired resistance to ALK inhibitors in EML4-ALK-positive non-small cell lung cancer.
Tanizaki J; Okamoto I; Okabe T; Sakai K; Tanaka K; Hayashi H; Kaneda H; Takezawa K; Kuwata K; Yamaguchi H; Hatashita E; Nishio K; Nakagawa K
Clin Cancer Res; 2012 Nov; 18(22):6219-26. PubMed ID: 22843788
[TBL] [Abstract][Full Text] [Related]
7. Activation of EGFR Bypass Signaling by TGFα Overexpression Induces Acquired Resistance to Alectinib in ALK-Translocated Lung Cancer Cells.
Tani T; Yasuda H; Hamamoto J; Kuroda A; Arai D; Ishioka K; Ohgino K; Miyawaki M; Kawada I; Naoki K; Hayashi Y; Betsuyaku T; Soejima K
Mol Cancer Ther; 2016 Jan; 15(1):162-71. PubMed ID: 26682573
[TBL] [Abstract][Full Text] [Related]
8. 17-AAG and 17-DMAG-induced inhibition of cell proliferation through B-Raf downregulation in WT B-Raf-expressing uveal melanoma cell lines.
Babchia N; Calipel A; Mouriaux F; Faussat AM; Mascarelli F
Invest Ophthalmol Vis Sci; 2008 Jun; 49(6):2348-56. PubMed ID: 18281615
[TBL] [Abstract][Full Text] [Related]
9. Efficacy of Hsp90 inhibition for induction of apoptosis and inhibition of growth in cervical carcinoma cells in vitro and in vivo.
Schwock J; Pham NA; Cao MP; Hedley DW
Cancer Chemother Pharmacol; 2008 Apr; 61(4):669-81. PubMed ID: 17579866
[TBL] [Abstract][Full Text] [Related]
10. [Effect and mechanism of silibinin on the inhibition of ALK positive NSCLC cells by sensitizing crizotinib].
Lin CC; Lu CH; Pan YH; Jiao L; Chen HY; Li L; He Y
Zhonghua Zhong Liu Za Zhi; 2017 Sep; 39(9):650-656. PubMed ID: 28926892
[No Abstract] [Full Text] [Related]
11. The Hsp90 inhibitor IPI-504 rapidly lowers EML4-ALK levels and induces tumor regression in ALK-driven NSCLC models.
Normant E; Paez G; West KA; Lim AR; Slocum KL; Tunkey C; McDougall J; Wylie AA; Robison K; Caliri K; Palombella VJ; Fritz CC
Oncogene; 2011 Jun; 30(22):2581-6. PubMed ID: 21258415
[TBL] [Abstract][Full Text] [Related]
12. The apoptotic effect and associated signalling of HSP90 inhibitor 17-DMAG in hepatocellular carcinoma cells.
Leng AM; Liu T; Yang J; Cui JF; Li XH; Zhu YN; Xiong T; Zhang G; Chen Y
Cell Biol Int; 2012 Oct; 36(10):893-9. PubMed ID: 22694478
[TBL] [Abstract][Full Text] [Related]
13. Acquired resistance to 17-allylamino-17-demethoxygeldanamycin (17-AAG, tanespimycin) in glioblastoma cells.
Gaspar N; Sharp SY; Pacey S; Jones C; Walton M; Vassal G; Eccles S; Pearson A; Workman P
Cancer Res; 2009 Mar; 69(5):1966-75. PubMed ID: 19244114
[TBL] [Abstract][Full Text] [Related]
14. Schedule-dependent synergy between the heat shock protein 90 inhibitor 17-(dimethylaminoethylamino)-17-demethoxygeldanamycin and doxorubicin restores apoptosis to p53-mutant lymphoma cell lines.
Robles AI; Wright MH; Gandhi B; Feis SS; Hanigan CL; Wiestner A; Varticovski L
Clin Cancer Res; 2006 Nov; 12(21):6547-56. PubMed ID: 17085670
[TBL] [Abstract][Full Text] [Related]
15. Comparison of inhibitory effect of 17-DMAG nanoparticles and free 17-DMAG in HSP90 gene expression in lung cancer.
Mellatyar H; Akbarzadeh A; Rahmati M; Ghalhar MG; Etemadi A; Nejati-Koshki K; Zarghami N; Barkhordari A
Asian Pac J Cancer Prev; 2014; 15(20):8693-8. PubMed ID: 25374192
[TBL] [Abstract][Full Text] [Related]
16. In vitro study comparing the efficacy of the water-soluble HSP90 inhibitors, 17-AEPGA and 17-DMAG, with that of the non‑water-soluble HSP90 inhibitor, 17-AAG, in breast cancer cell lines.
Ghadban T; Jessen A; Reeh M; Dibbern JL; Mahner S; Mueller V; Wellner UF; Güngör C; Izbicki JR; Vashist YK
Int J Mol Med; 2016 Oct; 38(4):1296-302. PubMed ID: 27498942
[TBL] [Abstract][Full Text] [Related]
17. 17-DMAG-loaded nanofibrous scaffold for effective growth inhibition of lung cancer cells through targeting HSP90 gene expression.
Mellatyar H; Talaei S; Pilehvar-Soltanahmadi Y; Dadashpour M; Barzegar A; Akbarzadeh A; Zarghami N
Biomed Pharmacother; 2018 Sep; 105():1026-1032. PubMed ID: 30021337
[TBL] [Abstract][Full Text] [Related]
18. Multiple receptor tyrosine kinase activation related to ALK inhibitor resistance in lung cancer cells with ALK rearrangement.
Choi SH; Kim DH; Choi YJ; Kim SY; Lee JE; Sung KJ; Kim WS; Choi CM; Rho JK; Lee JC
Oncotarget; 2017 Aug; 8(35):58771-58780. PubMed ID: 28938595
[TBL] [Abstract][Full Text] [Related]
19. HSP90 inhibitor, DMAG, synergizes with radiation of lung cancer cells by interfering with base excision and ATM-mediated DNA repair.
Koll TT; Feis SS; Wright MH; Teniola MM; Richardson MM; Robles AI; Bradsher J; Capala J; Varticovski L
Mol Cancer Ther; 2008 Jul; 7(7):1985-92. PubMed ID: 18645008
[TBL] [Abstract][Full Text] [Related]
20. Heat shock protein 90 inhibitors: new mode of therapy to overcome endocrine resistance.
Wong C; Chen S
Cancer Res; 2009 Nov; 69(22):8670-7. PubMed ID: 19861537
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]